For: | Inagaki C, Maeda D, Kimura A, Otsuru T, Iwagami Y, Nishida N, Sakai D, Shitotsuki R, Yachida S, Doki Y, Satoh T. Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report. World J Gastrointest Oncol 2019; 11(9): 761-767 [PMID: 31558980 DOI: 10.4251/wjgo.v11.i9.761] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v11/i9/761.htm |
Number | Citing Articles |
1 |
Amol Patel, Arti Sarin, Raghunath Marimuthu, Charan Sai Madarapu, A.G. Pandit, Divya Shelly, J. Sharanya, Vidya Veldore, P. Suresh, T.V.S.V.G.K. Tilak. Heterogeneous ERBB gene pathways, their targeted treatment and possible molecular mechanisms of resistance in metastatic gallbladder cancer. Medical Journal Armed Forces India 2024; doi: 10.1016/j.mjafi.2024.01.006
|
2 |
|
3 |
|
4 |
Michael May, Alexander G. Raufi, Sina Sadeghi, Karen Chen, Alina Iuga, Yu Sun, Firas Ahmed, Susan Bates, Gulam A. Manji. Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. The Oncologist 2021; 26(8): 640 doi: 10.1002/onco.13800
|
5 |
Yanjun Sun, Junfeng Gong, Zhuang Li, Lin Han, Dengqun Sun. Gallbladder cancer: surgical treatment, immunotherapy, and targeted therapy. Postgraduate Medicine 2024; 136(3): 278 doi: 10.1080/00325481.2024.2345585
|
6 |
Sameer Gupta, Puneet Prakash, Vijay Kumar, Arun Chaturvedi, Shashwat Tiwari. Gallbladder Cancer. 2023; : 249 doi: 10.1007/978-981-19-6442-8_14
|
7 |
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu. Overview of current targeted therapy in gallbladder cancer. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-00324-2
|